Navigation Links
Genta Incorporated Announces Second Quarter 2008 Financial Results and Corporate Highlights
Date:8/7/2008

vents.html. For investors unable to participate in the live call, a replay will be available approximately two hours after the completion of the call, and will be archived for 30 days. Access numbers for this replay are: (800) 642-1687 (U.S. and Canada) and (706) 645-9291 (International); conference ID number is 57549066.

About Genta

Genta Incorporated is a biopharmaceutical company with a diversified product portfolio that is focused on delivering innovative products for the treatment of patients with cancer. Two major programs anchor the Company's research platform: DNA/RNA-based Medicines and Small Molecules. Genasense(R) (oblimersen sodium) Injection is the Company's lead compound from its DNA/RNA Medicines program. Genta is currently recruiting patients to the AGENDA Trial, a global Phase 3 trial of Genasense in patients with advanced melanoma. The leading drug in Genta's Small Molecule program is Ganite(R) (gallium nitrate injection), which the Company is exclusively marketing in the U.S. for treatment of symptomatic patients with cancer-related hypercalcemia that is resistant to hydration. The Company has developed G4544, an oral formulation of the active ingredient in Ganite, that has recently entered clinical trials as a potential treatment for diseases associated with accelerated bone loss. The Company is also developing tesetaxel, a novel, orally absorbed, semi-synthetic taxane that is in the same drug class as paclitaxel and docetaxel. Ganite and Genasense are available on a "named-patient" basis in countries outside the United States. For more information about Genta, please visit our website at: http://www.genta.com.

Safe Harbor

This press release may contain forward-looking statements with respect to business conducted by Genta Incorporated. By their nature, forward-looking statements and forecasts involve risks and uncertainties because they relate to events and depend o
'/>"/>

SOURCE Genta Incorporated
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related biology technology :

1. Genta Announces Second Quarter 2008 Financial Results and Conference Call
2. Genta Receives Notice of Allowances for European Patents Related to Composition and Processes for Tesetaxel, a Leading Oral Taxane
3. Genta Submits NDA Amendment to FDA for Genasense as Treatment of Chronic Lymphocytic Leukemia
4. Genta Secures Up to $40 Million Convertible Financing Facility to Fund Key Programs
5. Genta Incorporated Announces First Quarter 2008 Financial Results and Corporate Highlights
6. Genta Announces Transfer of its Common Stock to the OTC Bulletin Board
7. Genta Announces Pending Transfer of its Common Stock to the Over-the-Counter Bulletin Board
8. Dr. Elizabeth Brown Joins Argenta TEC
9. Syngenta To Build Major Global Biotech Research Center in Beijing, China
10. Genta Restructures Operations to Focus on Priority Initiatives
11. Genta Granted Extension to Achieve Compliance with NASDAQ Listing Requirements
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/22/2014)... 2014 The Global and China Diabetes ... the current state of the Diabetes Drug industry in ... overview of the industry, including definitions, applications and industry ... analysis are provided with a focus on history, developments, ... between the international and Chinese situation is also offered. ...
(Date:8/22/2014)... August 22, 2014 The AMA is ... its members in Alaska that Alaska Governor Sean Parnell ... 15, further defining public use of Unmanned Aircraft Systems ... Force. House Bill 255states that it is, “An Act ... captured by an unmanned aircraft system.” It defines State ...
(Date:8/22/2014)... (PRWEB) August 22, 2014 “Our ... acknowledgement is a national disgrace. Furthermore, every governmental ... establishing the current, deplorable state of unorganized dysfunction ... great mistakes," to merely serve as a device ... extent of colossal failure(s) that have accumulated through ...
(Date:8/21/2014)... at the Institute for Molecular Medicine Finland (FIMM), ... developed a novel "man and machine" decision support ... aid was described in PLOS One ... based on computer vision algorithms similar to those ... of only the diagnostically most relevant areas. Tablet ...
Breaking Biology Technology:Diabetes Drugs Industry Growth Analysis in Global, China Regions Research Report Available at DeepResearchReports.com 2Diabetes Drugs Industry Growth Analysis in Global, China Regions Research Report Available at DeepResearchReports.com 3State of Alaska Signs Unmanned Aircraft Systems Bill 25 Great Mistakes in Healthcare and How to Fix Them by Dr. Ira Williams 2A novel 'man and machine' decision support system makes malaria diagnostics more effective 2
... Inc., a medical device,company that has developed a ... announced today that they have successfully raised $1.4,million ... Chief,Executive Officer, Clark Adams stated, "Valor,s Board and ... will be used to complete,clinical trials needed for ...
... 6 Halozyme Therapeutics, Inc.,(Nasdaq: HALO ), ... extracellular matrix for the drug delivery,endocrinology, oncology, and ... and nine months ended September 30, 2008., ... and I am,pleased with the initiation of our ...
... 6 NutraCea (OTC Bulletin Board:,NTRZ), a world ... and,technology announced today that it has appointed Olga ... Todd Crow, in accordance with,his previously announced intentions, ... a consulting and advisory capacity., Ms. Hernandez-Longan ...
Cached Biology Technology:Halozyme Therapeutics Reports 2008 Third Quarter Financial Results 2Halozyme Therapeutics Reports 2008 Third Quarter Financial Results 3Halozyme Therapeutics Reports 2008 Third Quarter Financial Results 4Halozyme Therapeutics Reports 2008 Third Quarter Financial Results 5Halozyme Therapeutics Reports 2008 Third Quarter Financial Results 6Halozyme Therapeutics Reports 2008 Third Quarter Financial Results 7Halozyme Therapeutics Reports 2008 Third Quarter Financial Results 8NutraCea Appoints New Chief Financial Officer 2
(Date:8/22/2014)... French . NAIROBI (22 ... soils looming as a major threat to food security across ... the last five years, 1.7 million African farmers in 13 ... hectares and helped them double or even triple crop yields. ... in Africa (AGRA) focuses on intensive efforts initiated five years ...
(Date:8/22/2014)... 2014 Diabetes affects nearly 10 percent of ... diabetics: constant finger pricking to test blood glucose ... reports the development of a protein that could ... for diabetes patients. In the American Chemical Society,s ... shows off her "designer protein" that could eventually ...
(Date:8/22/2014)... MD FASEB MARC (Maximizing Access to Research Careers) ... FASEB Grant Writing Seminar & Practical Exercises Workshop which ... Bethesda, Maryland from August 25-26, 2014. These awards ... and research scientists from underrepresented groups in the the ... This year MARC conferred 11 awards totaling $20,350. , ...
Breaking Biology News(10 mins):Effort to confront Africa's soil health crisis helps millions of farmers triple yields 2Effort to confront Africa's soil health crisis helps millions of farmers triple yields 3Effort to confront Africa's soil health crisis helps millions of farmers triple yields 4
... light on the causes of Parkinson,s disease, researchers report that ... mitochondria. A shutdown in fuel can have devastating effects on ... energy despite making up only 2 percent of body weight. ... FDA approved drugs early on may prevent or delay the ...
... CAMBRIDGE, Mass. -- By creating a better way to ... with MIT,s Picower Institute for Learning and Memory and the ... synapse formation. These studies could also help further understanding of ... and Fragile X syndrome. The study will appear in the ...
... their dosages may be standardized, but not every patient ... personal genetic characteristics of individuals and populations can explain ... not another, so medical researchers are adopting the new ... lab is leading the way. Dr. Noam ...
Cached Biology News:In Parkinson's disease, brain cells abandon mitochondria, researchers report 2In Parkinson's disease, brain cells abandon mitochondria, researchers report 3MIT researchers develop a better way to see molecules at work in living brain cells 2An X-ray for your genes 2
... Set from different human fetal normal ... maybe available upon request. Customers ... the whole set, and pay 70% ... All Dr. P Set products are ...
... Steady gravity-fed delivery of buffer and ... perfusion. Rat version. In Vivo Manual ... gravity-fed delivery of buffer and fixative ... to setup, use and clean--Complete system ...
Mouse IL-31 RA Biotinylated Affinity Purified PAb...
... assay system offers the following ... for batch-processing systems, Long lasting ... microplates such as 384-well and ... storage conditions ( 2 - ...
Biology Products: